Sherry Korczynski, Chief Commercial Officer of Aquestive Therapeutics, Inc. (NASDAQ:AQST), filed a Form 4 on September 11, 2026, disclosing the exercise of stock options and a same-day sale of 8,750 shares of common stock on September 9, 2026.

Key Highlights

  • Option exercise: Korczynski acquired 8,750 shares of common stock via exercise of a Non-Qualified Stock Option at an exercise price of $2.65 per share on September 9, 2026.
  • Share sale: 8,750 shares were disposed of at $5.22 per share on the same date under a Rule 10b5-1 trading plan previously adopted by the reporting person.
  • Remaining ownership: Following the transactions, Korczynski directly holds 235,689 shares of common stock.
  • Derivative securities: 26,250 Non-Qualified Stock Options remain beneficially owned, with an expiration date of March 7, 2035.
  • Vesting schedule: The options vest in three annual installments: 25% on the first, 25% on the second, and 50% on the third installment.

Korczynski's Option Exercise and Sale at Aquestive Therapeutics

According to the filing, Sherry Korczynski, serving as Chief Commercial Officer of Aquestive Therapeutics, Inc., executed two linked transactions on September 9, 2026. She first exercised a Non-Qualified Stock Option, acquiring 8,750 shares of common stock at a conversion price of $2.65 per share (transaction code M), bringing her directly held shares to 244,439 at that point.

In a simultaneous transaction, the filing reports that Korczynski sold all 8,750 of those shares at a price of $5.22 per share (transaction code S), reducing her direct beneficial ownership to 235,689 shares of common stock. The filing notes that the sale "was effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person." The Form 4 also indicates that the filing was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Separately, the filing discloses that 26,250 Non-Qualified Stock Options with an exercise price of $2.65 and an expiration date of March 7, 2035 remain beneficially owned by Korczynski following the reported transactions. Those remaining options vest across three annual installments: 25% on the first installment, 25% on the second installment, and 50% on the third installment. The Form 4 was signed by Thomas Zalewski as Attorney-In-Fact and filed on September 11, 2026.

What Was Disclosed

The filing discloses a same-day option exercise and share sale by Aquestive Therapeutics' Chief Commercial Officer on September 9, 2026, conducted under a pre-established Rule 10b5-1 trading plan, with 235,689 shares and 26,250 options remaining directly held afterward.